NEW YORK (360Dx) – Siemens Healthineers and Hill-Rom today announced a comarketing deal to bridge gaps in diabetes care and satisfy value-based quality measures.
The offering will include Siemens Healthineers' DCA Vantage Analyzer for HbA1c testing and Clinitek Status + Urine Chemistry Urine Analyzer for kidney checks, and Hill-Rom's Welch Allyn RetinaVue Network and imaging technology for teleretinal exams.
Financial and other terms of the deal were not disclosed.
The solution, the partners said, will provide physicians more control over patient care by allowing for more proactive testing and treatment, and the workflow could reduce costs and eliminate inconvenient follow-up visits.
Siemens Healthineers' DCA Vantage Analyzer monitors patients' glycemic controls in minutes with a CLIA-waived HbA1c testing, while the Clinitek Status + Urine Chemistry Analyzer allows healthcare providers to perform a kidney check in 60 seconds with a CLIA-waived albumin-to-creatinine ratio testing, the partners said.
"Our new commercial relationship with Hill-Rom will provide holistic, easy-to-implement solutions that aid in combating diabetes and related comorbidities while satisfying value-based quality care measures," said Mike Sampson, senior vice president of Point of Care Diagnostics, North America, Siemens Healthineers. "With operator-friendly analyzers that generate lab-quality results in minutes and capabilities to integrate test results with electronic health records, physicians can make immediate treatment decisions and improve long-term outcomes."